EP
VKTX icon

Essential Partners’s Viking Therapeutics VKTX Stock Holding History

Essential Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$858 Buy
+22
New +$711 ﹤0.01% 2308

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Essential Partners's VKTX Position: Q2 2026 in Review

Essential Partners opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 22 shares worth $858. The stake represents ﹤0.01% of the portfolio and ranks #2308 among its holdings.

432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Essential Partners held 22 shares of Viking Therapeutics worth $858 as of Q2 2026.
  • Viking Therapeutics was a new Essential Partners position in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2308 holding.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.